Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by gudisgoodon Aug 09, 2024 3:45am
265 Views
Post# 36170839

Q2/24 Comments

Q2/24 CommentsI liked the report and the earnings call:

+ Meaningful increase of guidance -> good progress with sales.
+ Speeding up the pipeline.
+ Relationship with the Brazilian government (nice to hear!).
+ Continued buybacks (although the volume is low right now).

GUD is gearing up for an impressive number of launches next year. And, as always, the potential for further product acquisitions / M&A is always there, and will eventually happen. The discipline they have for these deals is a big reason for why I like the management.

What did you think about the report?
<< Previous
Bullboard Posts
Next >>